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Inanattempt toimproveTRAIL’s (tumor necrosis factor-related apoptosis-inducingligand)tumorselective activity a variant was
designed, in which the three TRAIL protomers are expressed as a single polypeptide chain (scTRAIL). By genetic fusion with a
single-chain antibody fragment (scFv) recognizing the extracellular domain of ErbB2, we further equipped scTRAIL with tumor-
targeting properties. We studied tumor targeting and apoptosis induction of scFv–scTRAIL in comparison with
non-targeted scTRAIL. Importantly, the tumor antigen-targeted scTRAIL fusion protein showed higher apoptotic activity in
vitro, with a predominant action by TRAIL-R2 signaling. Pharmacokinetic studies revealed increased plasma half-life of the
targeted scTRAILfusion proteincomparedwithscTRAIL.InvivostudiesinamousetumormodelwithxenotransplantedColo205
cells conﬁrmed greater response to the ErbB2-speciﬁc scTRAIL fusion protein compared with non-targeted scTRAIL both under
local and systemic application regimen. Together, in vitro and in vivo data give proof of concept of higher therapeutic activity of
tumor-targeted scFv–scTRAIL molecules. Further, we envisage that through targeting of scTRAIL, potential side effects should
beminimized. We proposethat scFv-mediatedtumortargeting of single-chain TRAIL represents a promising strategy to improve
TRAIL’s antitumoral action and to minimize potential unwanted actions on normal tissues.
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Although for many malignancies traditional cytotoxic chemo-
therapy is still the treatment of choice, targeted therapies
gain increasing importance because they are expected
to exert higher tumor-speciﬁc activity and less dose-limiting
side effects. The anti-CD20 antibody Rituximab and the
Bcr-Abl-selective kinase inhibitor Gleevec, respectively, are
two vivid examples for the success of targeted therapy (for
review, see Gerber
1). Targeting the apoptotic machinery of
malignant cells has become an attractive concept, beginning
with tumor necrosis factor (TNF) and its now established
clinical use for locoregional treatment of limb metastases
of soft tissue sarcoma and melanoma
2 and followed by
the current exploitation of other proapoptotic members of the
TNF ligand family – CD95L and TNF-related apoptosis-
inducing ligand (TRAIL) – being presently at various stages
of preclinical and clinical development (for review, see Call
et al.,
3 Gerspach et al.
4 and Newsom-Davis et al.
5). TRAIL,
similar to TNF a type II transmembrane protein, is expressed
on various immune effector cells and appears critically
involved in antitumor responses in the body.
6 It is probably
the best candidate of a death ligand for systemic application
because preclinical studies revealed that, in contrast to
TNF and CD95 agonists, the application of trimeric, soluble
TRAILiswelltolerated.Concomitantly,itdemonstratedpotent
antitumor activity in tumor models based on tumor cell lines
and primary tumor samples.
7–10 Although ﬁrst clinical trials in
various advanced cancers are promising, as stable disease
has been reported in many cases, TRAIL monotherapy
most likely will not result in a sufﬁcient overall therapeutic
activity.
11 Concurrently, this faces the potential problem
that under combined treatment options normal cells might
also be sensitized to TRAIL-induced apoptosis (reviewed
by Falschlehner et al.
12). Furthermore, we have recently
shown that TRAIL-R1 is activated by the soluble as well as
the membrane-bound form of the ligand, whereas TRAIL-R2
is preferentially activated by membrane TRAIL or oligo-
merized soluble trimeric TRAIL.
13,14 As agonistic TRAIL-R2-
speciﬁc antibodies likewise display potent antitumor activity
(reviewed by Johnstone et al.
15), it is conceivable that
homotrimeric TRAIL could be improved in its activity provided
efﬁcient TRAIL-R2 signaling is ensured through genetic modi-
ﬁcations or other means. On the other hand, the spontaneous
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www.nature.com/cddisaggregation of some recombinant TRAIL preparations,
resembling secondarily crosslinked TRAIL, has been asso-
ciated with unwanted actions on normal tissues and
thus curtail their use as tumor-selective apoptosis inducers
(reviewed by Koschny et al.
16). Thus, TRAIL variants
mimicking the full bioactivity of membrane TRAIL could
present powerful cancer therapeutics provided that a tumor-
restrictedactioncanbeachieved.Afurtherapparentlimitation
of the currently clinically investigated recombinant TRAIL
reagents is their rather short in vivo half-life. Therefore, an
improvement of pharmacokinetic properties might also lead to
increased therapeutic action. A potential solution to increase
speciﬁcactivityand bioavailability isthe combination ofTRAIL
function with tumor targeting. Thus, we generated new TRAIL
fusion proteins containing an antibody fragment (single-chain
Fv fragment (scFv)) for targeting TRAIL to the tumor to enrich
the therapeutic at the tumor site and to enhance its speciﬁc
bioactivity. ErbB2, similar to EGFR/ErbB1, ErbB3 and ErbB4
belonging to the ErbB receptor tyrosine kinase family,
represents a clinically relevant target antigen. It is highly
expressed on a variety of human solid tumors (reviewed by
Holbro and Hynes
17) and there is already one humanized
monoclonal antibody (mAb) directed against the extracellular
domain of ErbB2 in clinical use (Trastuzumab) and approved
for treatment of breast carcinoma. Several other mAbs are
in different stages of clinical evaluation (reviewed by
Baselga and Swain
18). Although the clinical data provide
clear evidence that ErbB2 is a relevant target, they also show
that the therapeutic effect of the current antibody reagents
is rather limited.
19 This justiﬁes the search for additional
ErbB2-targeted strategies.
Recently, a single-chain TNF molecule, consisting of three
TNF monomers fused by short peptide linkers, was described
to exert enhanced stability and antitumoral activity.
20 We
have designed an analogous single polypeptide chain
TRAIL variant (scTRAIL), which was used to construct a
scFv–scTRAIL fusion protein for tumor targeting. We have
compared the bioactivities of this fusion protein with non-
targeted scTRAIL in in vitro and in vivo tumor models. We
show here that the tumor antigen-targeted scTRAIL fusion
protein showed higher apoptotic activity to scTRAIL in vitro,
with a predominant action by TRAIL-R2 signaling on Colo205
colon carcinoma cells. In vivo studies in a mouse xenograft
tumor model conﬁrmed signiﬁcantly higher response to the
tumor-targeted ErbB2-speciﬁc scTRAIL fusion protein.
Results
Construction and production of TRAIL fusion proteins.
To generate a single-chain TRAIL molecule, we followed the
design principle described for scTNF
20 and covalently fused
three TRAIL monomers, each consisting of the extracellular
domain of TRAIL (aa 95–281) through two peptide linkers
comprising four repeats of the sequence GGGS (Figure 1a).
To facilitate puriﬁcation and analysis an N-terminal FLAG
tag was added. Furthermore, by additional N-terminal
fusion of a single-chain antibody fragment (scFv) recognizing
the FRP5 epitope within the extracellular domain of ErbB2,
21
we generated an ErbB2-speciﬁc scTRAIL fusion protein
(Figure 1a).
Both scTRAIL and scFv–scTRAIL were puriﬁed by afﬁnity
chromatography on monoclonal M2 anti-FLAG agarose from
the supernatant of stably transfected HEK293 cells with yields
of about 1mg protein per liter cell culture supernatant.
Immunoblot analysis and SDS-PAGE (Figure 1b) of the
puriﬁed protein showed single protein bands with a molecular
mass of B70kDa for scTRAIL and B100kDa for scFv–
scTRAILmatchingtheexpectedcalculatedmolecularmasses
of71and 98kDa,respectively. Gel ﬁltrationanalysis indicated
a monomeric organization of both scTRAIL variants, corres-
ponding, with respect to the TRAIL part, to a noncovalently
assembled trimer of a conventional recombinant TRAIL
molecule (Figure 1c). The molecular masses deduced from
SEC were slightly lower compared with that derived from
SDS-PAGE (Figure 1b), which did not result from degradation
as veriﬁed by immunoblot analysis of collected fractions
(Figure 1c). In the scTRAIL preparation, the minor fraction
eluting in SEC at apparent higher molecular weight, thus
potentially comprising aggregated complexes, did not display
disproportionately high bioactivity, as revealed from compa-
rison of cytotoxic activity of fraction 2 and 15, taking relative
protein amounts into consideration (data not shown).
Target antigen-speciﬁc binding of scFv–scTRAIL. To
analyze speciﬁc binding of scFv–scTRAIL to ErbB2-positive
cells, ﬂow cytometry analysis was performed. ErbB2 expres-
sion analysis conﬁrmed a median versus low expression
level for Colo205 colon carcinoma and HT1080 ﬁbrosarcoma
cells, respectively (Figure 2a), compared with SKBR3 cells
that are well-known to highly express the ErbB2 protein (data
not shown).
22 Incubation of Colo205 and HT1080 cells with
the fusion protein revealed a speciﬁc, binding to ErbB2-
positive cells (Figure 2a and b) compared with incubation
with the non-targeted scTRAIL, which resulted only in a weak
ﬂuorescence signal, either by detection with anti-TRAIL
(Figure 2a) or with anti-FLAG antibodies (data not shown).
As binding of homotrimeric FLAG-tagged TRAIL showed
similar weak signals (data not shown), this could reﬂect
a low level of TRAIL receptor (TRAILR) expression on the
investigated target cells and/or insufﬁcient sensitivity of
FACS analyses. ErbB2-speciﬁc binding was conﬁrmed by
using TRAILR1- and R2-Fc fusion proteins for detection
of scFv–scTRAIL binding to target cells (Figure 2b) and
competition with anti-ErbB2 antibodies (FRP5). This led to
a near complete inhibition of scFv–scTRAIL binding to the
ErbB2-positive cell line (Figure 2b).
Target antigen-restricted induction of cell death by
scFv–scTRAIL. To address the bioactivity of scFv–
scTRAIL in vitro, we ﬁrst analyzed induction of cell death
on ErbB2-negative SKW6.4 cells, which are known to be
TRAIL-R1 and TRAIL-R2 positive
23,24 (Figure 3a). Although
scTRAIL and scFv–scTRAIL did not show cytotoxic activity
up to 8nM, respectively, in the presence of the crosslinking
anti-FLAG antibody M2 comparable bioactivities of both
fusion proteins were observed (Figure 3a). In contrast, incu-
bation of ErbB2-positive Colo205 and HT1080 cells
with scTRAIL or scFv–scTRAIL revealed an approximately
three- to ﬁvefold higher bioactivity of the ErbB2-speciﬁc
scFv–scTRAIL compared with the non-targeted scTRAIL
Tumor-targeted single-chain TRAIL for cancer therapy
B Schneider et al
2
Cell Death and Disease(Figure3b;Colo205:EC50scFv–scTRAIL:30±10pM,EC50scTRAIL:
130±70pM; HT1080: EC50scFv–scTRAIL:5 0 ±5pM,EC50 scTRAIL:
140±10pM). Furthermore, bioactivity of the targeted
scFv–scTRAIL compared well with that of a commercially
available high activity TRAIL, the so-called ‘Killer-TRAIL’,
with about twofold higher (Colo205) or at least comparable
(HT1080) activity of the scFv–scTRAIL reagent (Figure 3c).
Furthermore, on target-negative SKW6.4 cells, the second-
arily crosslinked scTRAIL or scFv–scTRAIL displayed
comparable cytotoxic activity to ‘Killer-TRAIL’ (data not
shown). From blocking studies using anti-ErbB2 anti-
bodies (FRP5, Figure 3d) or recombinant ErbB2 peptides
comprising the epitope of the erbB2-speciﬁc scFv
21
(Figure 3e), it became evident that the increased bioactivity
depended on ErbB2 target binding. Preincubation with FRP5
or ErbB2 peptides before addition of the ErbB2-speciﬁc
scFv–scTRAIL fusion protein restored cell viability of
Colo205 and HT1080 cells to a signiﬁcant extent (Figure 3d
and e). Furthermore, as for both tested cell lines TRAIL-
induced cell death is primarily mediated by TRAIL-R2,
13,25
the higher bioactivity of the scFv–scTRAIL on ErbB2-positive
cells pointed to a membrane TRAIL-mimetic activity upon
speciﬁc cell surface immobilization of the fusion protein (see
below). Furthermore, inhibition of TRAIL bioactivity of the
scFv–scTRAIL by the use of a TRAIL-neutralizing antibody led
to complete restoration of cell viability of Colo205 and HT1080
cells (Figure 3f). Thus, the ErbB2-speciﬁc scFv domain per se
did not directly contribute to apoptosis induction.
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Figure 1 Biochemical analysis of scTRAIL and scFv–scTRAIL. (a) Scheme of the scTRAIL fusion proteins used in this study. L, leader peptide; scFv, human ErbB2-
speciﬁc single-chain antibody fragment; F, FLAG tag; TRAIL, human TRAIL (aa 95–281). (b) Puriﬁed scTRAIL (lane 1) and scFv–scTRAIL (lane 2) were analyzed by
SDS-PAGE (10%, reducing conditions) followed by immunoblot analysis (left, 250ng protein/lane) or silver staining (right, 1mg protein/lane). For immunoblotting,
the monoclonal anti-FLAG M2 antibody and an alkaline phosphatase-conjugated secondary antibody was used. (c) The TRAIL variants were separated by gel ﬁltration on a
BioSuite250column.Dottedlinesindicatetheretentiontimeofthemolecularweightstandardsapoferritin(443kDa),b-amylase(200kDa),bovineserumalbumin(66kDa)and
carbonic anhydrase (29kDa). Collected fractions were analyzed by immunoblotting as in b. For scTRAIL fractions 1–9 (every second fraction; ﬁrst part), fractions 11–16
(second part) and fractions 19–26 (every second fraction; third part) were immunoblotted. For scFv–scTRAIL fractions 8–24 were immunoblotted
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Cell Death and DiseaseTRAIL-R2-mediated apoptosis induction of scFv–
scTRAIL. In absence of the ErbB2 antigen, crosslinking of
scFv–scTRAIL by its internal FLAG tag with the FLAG-speciﬁc
mAb M2 was necessary to induce cell death in SKW
(Figure 3a) and in Jurkat cells (Figure 4a). Thus, similar to
homotrimeric TRAIL, secondary crosslinking conferred TRAIL-
R2-stimulating capacity, conﬁrming the nonaggregated state
of the single-chain fusion protein with a TRAIL domain resem-
bling a trimeric soluble TRAIL. The ErbB2-positive Colo205
and HT1080 cells express both, TRAIL-R1 and -R2. To deﬁne
through which of the two TRAIL death receptors the
scFv–scTRAIL molecule signals apoptosis, neutralization
experiments with antagonistic, TRAIL-R2-speciﬁc monovalent
antibody fragments (Fab fragments) were performed. Both
ErbB2-positive cell lines showed dominant TRAIL-R2-
mediated cell death at low concentrations of scFv–scTRAIL
(Figure 4b), demonstrating that cell surface immobilized scFv–
scTRAIL exerted membrane TRAIL-like activity, similar to what
has been previously described for conventional scFv–TRAIL
fusion proteins.
13,26,27 The concentration of anti-TRAIL-R2
Fab fragments used in these experiments was sufﬁcient to
almost completely block cell death of Jurkat cells induced
by secondary crosslinked, homotrimeric FLAG-tagged TRAIL
(Figure 4b). In addition, cell surface antigen-bound scFv–
scTRAIL also activated the murine TRAILR, which is, similarly
to human TRAIL-R2, not or hardly activated by soluble TRAIL.
This was shown by mixed cultures using equal numbers of
Colo205 cells and L929 mouse ﬁbroblasts (Figure 4c). The
latter do not express human ErbB2 and thus, in contrast to
Colo205 cells, are not able to immobilize the scFv–scTRAIL by
the ErbB2-targeting domain. Thus, if scFv–scTRAIL is able to
induce cell death in L929 cells by mimicking membrane TRAIL
after binding to the ErbB2 receptor on Colo205 cells, more
than 50% of the cells are expected to die. Indeed, incubation
with scFv–scTRAIL induced cell death in over 70% cells of the
co-culture, whereas equal molar amounts of scTRAIL induced
cell death in only about 30% of the mixed cells (Figure 4c). In
monocultures, the same concentration of scFv–scTRAIL and
scTRAIL induced cell death in about 90% of Colo205 cells,
respectively, but not in L929 cells, conﬁrming that, in the
soluble form, both proteins are non-toxic to the latter (data not
shown). Furthermore, due to the lack of human ErbB2, the
L929 cells might also be considered as antigen-negative
bystander cells, potentially occurring in a tumor tissue. Thus,
scFv–scTRAIL bound to antigen is expected to elicit an
antitumoral effect also on neighboring antigen-negative cells
within the tumor environment.
Serum half-life of scFv–scTRAIL. To evaluate the pharmaco-
kinetic characteristics of scFv–scTRAIL in comparison with
scTRAIL, serum samples were collected after a single dose
intravenous (i.v.) injection of 400pmol into Balb/c mice. The
relative serum concentrations plotted over time ﬁtted well to
a two-phase exponential decay regression curve in both
cases. Within 20min post-injection, both TRAIL variants
displayed similar kinetics with a serum half-life of B35min
(t1
2a), respectively. At later time points, a slight but signiﬁcant
difference in bioavailability was detected with half-lifes (t 1
2b)
of 160 and 124min and AUCs of 11191 and 8125 for scFv–
scTRAIL and scTRAIL, respectively (Figure 5a). Thus, the
ErbB2-speciﬁc fusion protein was more efﬁciently retained in
the bloodstream, which might positively affect therapeutic
activity.
Tumoricidal effects on human colon carcinomas in nude
mice. To investigate whether the improved target antigen-
restricted tumoricidal activity of scFv–scTRAIL observed
in vitro is effective in vivo, in a ﬁrst experiment a local
treatment strategy was applied. NMRI nu/nu mice were
injected subcutaneously (s.c.) with Colo205 cells. Treatment
commenced 8 days later when vascularized tumor could be
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Figure 2 Target antigen-speciﬁc binding of scFv–scTRAIL. (a) ErbB2
expression of Colo205 and HT1080 cells: 5 10
5 cells were incubated with
anti-ErbB2 (gray ﬁlled) or isotype control antibody (black lines) followed by
FITC-conjugated anti-mouse antibody and ﬂuorescence intensity was measured by
FACS analysis. Binding of scFv–scTRAIL to ErbB2-positive Colo205 and HT1080
cells compared with non-targeted scTRAIL: 5 10
5 cells were incubated with
50nM scTRAIL(gray lines) or 50nM scFv–scTRAIL (gray ﬁlled) and, after repeated
washes, bound proteins were detected using anti-human TRAIL mAb and
FITC-labeled anti-mouse IgG. As control, cells treated with anti-humanTRAIL mAb
andFITC-labeledanti-mouseIgGwereused(blacklines).(b)Bindingcompetitionof
scFv–scTRAIL to ErbB2-positive Colo205 cells by ErbB2-speciﬁc antibodies:
5 10
5 Colo205 or HT1080 cells were preincubated with FRP5 or mouse IgG1
(10mg/ml, respectively) before addition of scFv–scTRAIL (50nM). Detection was
carried out by TRAILR-Fc fusion proteins and FITC-labeled anti-human IgG,
Fc-speciﬁc antibodies. Shown are X-fold increased mean ﬂuorescence intensities
(MFI) compared with the control (FITC-labeled anti-human Fc) from three
independent experiments (mean±S.D.). Statistical analysis was carried out with
unpaired t-test, two-tailed test, **P¼0.0021, ***Po0.0001
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Cell Death and Diseaseclearly discerned. Regimen was 4 daily s.c. injections of
1nmol of scTRAIL and scFv–scTRAIL, respectively, in an
area close to the established tumors. Tumor growth was
monitored for 22 days. With this treatment protocol, we
observed signiﬁcant tumor regression in the scFv–scTRAIL-
treated group compared not only with the control group
(days 1–19; e.g., day 11, **P¼0.003) but also with the non-
targeted scTRAIL-treated group (days 1–11; e.g., day 11,
*P¼0.04, Figure 5b). These data are in accordance with one
pilot experiment also showing signiﬁcantly reduced tumor
growth up to 11 days after scFv–scTRAIL treatment started
(**Po0.003, data not shown). These data prompted studies
with a systemic treatment protocol to assess the feasibility
of such fusion proteins for potential clinical use. Again
treatment was initiated when a solid, vascularized tumor
had been established. Mice received 8 daily i.v. injections
of 1nmol of the TRAIL fusion proteins or control injections.
All treatments were well tolerated by the animals, and we
observed no weight loss or other obvious signs of systemic
toxicity. Tumor size in control mice increased progressively
over the study period (Figure 5c). Similar to the peritumoral
treatment, systemic application of the two TRAIL reagents
resulted in clear antitumoral activity during treatment. We
observed signiﬁcantly delayed tumor growth on scTRAIL
treatment compared with control groups (days 1–19), and
an even stronger effect for the tumor-targeted scFv–scTRAIL
fusion protein (days 1–19). Remarkably, during scFv–
scTRAIL treatment a clear reduction in tumor size was
recorded, which resulted in a signiﬁcantly enhanced anti-
tumoral effect compared with non-targeted scTRAIL (days
1–19). Although tumors of both treatment groups began to
re-grow shortly after discontinuation of treatment, these
differences remained signiﬁcant during the complete obser-
vation period (e.g., day 19 (Figure 5c)).
Discussion
We here show thatthrough genetic engineering and targeting,
TRAIL’s antitumoral activity can be improved. TRAIL is
considered as a tumor-selective agent, as cells from normal
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Figure 3 Target antigen-dependent bioactivity of scFv–scTRAIL. (a) Bioactivity
on target antigen-negative cells. 2 10
4 SKW6.4 cells/well were seeded in 96-well
plates. The next day, cells were treated with serial dilutions of the fusion proteins in
the presence or absence of anti-FLAG M2 antibody (2mg/ml). (b) Bioactivity of
scTRAIL versus scFv–scTRAIL. 5 10
4 Colo205 or 2 10
4 HT1080 cells/well
were seeded in 96-well plates. The following day, cells were treated with 2.5mg/ml
cycloheximide and challenged in duplicates with increasing concentrations of
scTRAIL and scFv–scTRAIL, respectively. After over night incubation, cell viability
was determined by MTT assay or KV staining. Results from three to ﬁve
independent experiments are shown (mean±S.D.). (c) Bioactivity of scFv–
scTRAIL compared to ‘KillerTRAIL’: Same assay as in b but incubation with serial
dilutions of scFv–scTRAIL or ‘KillerTRAIL’. (d, e) Target antigen-dependent
apoptosis induction of scFv–scTRAIL: Same assay as in b with scFv–scTRAIL
titrated in the presence or absence of anti-ErbB2 (FRP5, 5mg/ml) (d) or with scFv–
scTRAIL (0.05nM) in the presence or absence of recErbB2 (10mg/ml) (e).
(f)ContributionofthescFvdomaininthescFv–scTRAILtoapoptosisinduction.Same
a s s a ya si nb with scFv–scTRAIL titrated in the presence or absence of neutralizing
anti-TRAIL antibodies (2E5, 1mg/ml). (a, c–f) Results from three independent
experiments are shown (mean±S.D.). (b, d) Statistical analysis was carried out with
unpaired t-test, two-tailed test, **0.0026 oP40.0098, ***Po0.0001
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Cell Death and Diseasetissue appear largely resistant toward apoptosis induction
by trimeric TRAIL derivatives,
8 and clinical studies so far
revealed that homotrimeric TRAIL is well tolerated.
28,29
However, in contrast to many investigated tumor cell lines,
diverse primary cancer cells are inherently resistant to
TRAIL-mediated apoptosis (reviewed by Newsom-Davis
et al.
5). Moreover, it has been demonstrated that TRAIL
may under certain conditions even promote survival, proli-
feration, migration and invasion in TRAIL-resistant tumor
cells.
30,31 Thus, combination therapy with other drugs will be
required, for example, for sensitization of apoptotic pathways
or suppression of potentially protumoral TRAIL effects, to
achieve major and lasting tumor remissions. In this context,
recentdataappearofrelevanceshowingthattheresistanceof
nontransformed cells toward the apoptotic action of TRAIL
may vanish, at least in some tissues such as the liver, when
these are subjected to various stress conditions, such
as infection and chemotherapeutics.
12,32–34 Recently, it has
also been shown that TRAIL-R2-mediated apoptosis might
substantially contribute to chronic cholestatic disease.
35
Accordingly, an improvement of the tumor-selective action
of TRAIL appears mandatory. Along this line, we and others
have already shown earlier that tumor-targeting approaches
through the generation of TNF ligand fusion proteins, which
aim to restrict TNF ligand’s full cytotoxic activity to the
cancerous tissue are very promising approaches to improve
therapeutic efﬁcacy of TRAIL and other members of the
TNF ligand family.
4 Conventional fusion proteins of TRAIL
and antibody-derived scFv fragments reveal homotrimeric
proteins with a molecular mass of B150kDa. This nearly
corresponds in size to complete antibodies that are reported
to penetrate tumor tissues slowly and nonuniformly.
36
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Figure 4 TRAIL-R2-mediated apoptosis induction of scFv–scTRAIL. (a)1 10
5 Jurkat cells/well were seeded in 96-well plates. The following day, cells were challenged
withtheindicatedconcentrationofscFv–scTRAILintheabsence(opensymbols)orpresence(ﬁlledsymbols)of1mg/mlofthecrosslinkinganti-FLAGmAbM2.Afteradditional
16h, cell viability was determined by MTT assay. (b) Cells (5 10
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4 HT1080, 1 10
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weretreatedwith2.5mg/mlcycloheximide(HT1080,Colo205)andchallengedwithscFv–scTRAIL(1.35nM)(HT1080,Colo205)or2nMTRAILþ1mg/mlanti-FLAGmAbM2
(Jurkat) in the presence or absence of TRAIL-R2 Fab (50mg/ml). After additional 16h, cell viability was determined by MTT assay or KV staining. (c)1 10
4 Colo205 and
1 10
4 L929 cells/well were seeded and co-cultured in 96-well plates. The next day, cells were treated with 2.5mg/ml cycloheximide and challenged with 1nM scTRAIL or
scFv–scTRAIL. After additional 16h, cell viability was determined by MTT assay. (a–c) Results from three independent experiments are shown (mean±S.D.)
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Cell Death and DiseaseFurthermore, antibody fragments may have an intrinsic
tendency to aggregate, thereby potentially leading to higher
order complexes, which in turn not only results in a further
increase in size but may also cause target-independent
TRAIL-R2 activity, too. To circumvent or at least minimize
these potential problems, we have developed a new format
of a TRAIL fusion protein based on scTRAIL, a single
polypeptide chain composed of three TRAIL monomers. Gel
ﬁltration and western blot analysis revealed that the ErbB2-
speciﬁc scFv–scTRAIL fusion protein could be expressed
in the expected monomeric state corresponding formally to
a trimeric TRAIL variant. This is of great importance, as
it became evident that the formation of high order complexes
and aggregates of recombinant forms of TRAIL (e.g.,
His-TRAIL, crosslinked FLAG–TRAIL) increases the toxicity
of the ligand to normal cells (reviewed by Koschny et al.
16).
As expected, the ErbB2-speciﬁc scFv–scTRAIL speciﬁcally
bound to ErbB2-positive cells. This could be conﬁrmed by the
use of TRAILR-Fc fusion proteins to detect the ErbB2 bound
scFv–scTRAIL and by blocking of fusion protein binding
with the ErbB2-speciﬁc antibody FRP5, thereby indicating
predominant binding of the fusion protein by the antibody
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Figure 5 Pharmacokinetic properties and antitumoral activity of scTRAIL and scFv–scTRAIL. (a) Reduced elimination of scFv–scTRAIL from circulation. scTRAIL and
scFv–scTRAIL were detected by ELISA in serum samples obtained at the indicated time points after i.v. injection into Balb/c mice. For each protein three mice were treated.
Signiﬁcant differences between both proteins were marked by asterisks. (b) Antitumoral activity in a xenograft tumor model – local treatment. NMRI nu/nu mice were injected
s.c. with 3 10
6 human colon carcinoma Colo205 cells. Treatment started when tumors reached about 25mm
2 (8 days after inoculation). Mice received four daily s.c.
injectionsof 1nmol of thecorresponding proteins beginningday 0. n¼7 tumorsper treatment group;symbols, meanof tumor volumes;bars,S.E.M.Individualtumor sizes at
day 11 with bars indicating the mean are shown on the right. (c) Antitumoral activity in a xenograft tumor model – systemic treatment. 3 10
6 Colo205 cells were s.c.
inoculated at the left and right dorsal site of NMRI nu/nu mice. Treatment started when tumors reached about 25mm
2 (5 days after inoculation). Mice received eight daily i.v.
injectionsof 1nmol of thecorresponding proteins beginningat day 0. n¼8 tumorsper treatment group;symbols, meanof tumor volumes;bars,S.E.M.Individualtumor sizes
at day 19 with bars indicating the mean are shown on the right
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Cell Death and Diseasemoiety to ErbB2 rather than by the TRAIL domain and
TRAIL-R. Compared with the non-targeted scTRAIL mole-
cule, the tumor antigen-targeted scTRAIL fusion protein
showed higher apoptotic activity in vitro on ErbB2-positive
cells. This target antigen-dependent cytotoxicity could be
conﬁrmed by preincubation with competing ErbB2-speciﬁc
antibody FRP5 or with ErbB2 peptide, restoring cell viability to
a signiﬁcant extent. We and others have previously described
that, compared with soluble homotrimeric TRAIL, homo-
trimeric scFv–TRAIL fusion proteins gain a higher activity on
TRAIL-R2 upon cell surface binding by the targeting domain
within the fusion proteins.
13,26,27 Of note, although there is
some controversial discussion on this, it has been shown
that efﬁcient activation of TRAIL-R2 is only reached by
natural membrane TRAIL, crosslinked soluble or cell
surface immobilized TRAIL.
13,26,27,37,38 Importantly, the
scFv–scTRAIL fusion protein likewise converted into a
functional equivalent of membrane TRAIL on target-antigen
binding, and thus efﬁciently induced cell death already at low
concentrations by TRAIL-R2, the predominant TRAIL-
induced apoptosis pathway in the cell lines studied here.
Accordingly, receptor binding and activation could be blocked
by TRAIL-R2-neutralizing monovalent Fab fragments. More-
over, Jurkat cells, which only express TRAIL-R2, but not
ErbB2 and TRAIL-R1 are resistant against soluble scFv–
scTRAIL, whereas crosslinking of the fusion protein led to an
increase in activity. These properties are especially important
based on observations that on tumor cells TRAIL-R2 is more
frequently and strongly expressed than TRAIL-R1,
39 that
apoptotic signaling through TRAIL-R2 may be more potent
than through TRAIL-R1
14 and that, on the other hand, TRAIL-
R2 may be a key regulator of cholestatic liver injury by
induction of apoptosis in cholangiocytes.
35 Consequently, the
scFv–scTRAIL might be an appropriate therapeutic, which
meets the criteria of high antitumor and low off-target activity.
In vivo analyses in mice revealed that, on i.v. injection, the
scFv–scTRAIL and the scTRAIL displayed biphasic pharma-
cokinetics. In the ﬁrst phase, the calculated t1
2a of B35min
was similar for both proteins. In the second phase, the scFv–
scTRAIL displayed a slightly increased half-life with t 1
2b
of B160min compared with 125min for the scTRAIL. This
strongly contrasts to some of the published data for homo-
trimeric TRAIL, indicating a half-life of 3–5min (t 1
2a) and
20min (t1
2b) in rodents.
40,41 Our results rather match with
pharmacokinetic data of LZ-TRAIL, a trimer-stabilized TRAIL
variant (t1
2a: 1.3h; t1
2b: 4.8h
8). Most important, both single-
chain TRAIL variants signiﬁcantly reduced growth of estab-
lished Colo205 tumors already at rather moderate doses,
either on local or systemic treatment. In accordance with the
in vitro bioactivity, the scFv–scTRAIL displayed superior
tumoricidal effects in vivo compared with the scTRAIL.
We propose that increased antitumoral activity is largely
related to ErbB2-mediated tumor enrichment and the target-
ing-dependent increase in bioactivity rather than the slightly
increased bioavailability. The observed re-growth of tumors
upon cessation of treatment has also been reported with
homotrimeric TRAIL and might overcome when the combi-
nation treatments with appropriate chemotherapeutics are
conducted.
9,10,40 Furthermore, we can exclude an effect of
the ErbB2-speciﬁc antibody fragment scFvFRP5 on tumor
growth, as addition of TRAIL-neutralizing antibodies comple-
tely restored cell viability on incubation with scFv–scTRAIL.
This is in accordance with previous reports showing that the
mAb FRP5 did not affect tumor growth in vivo, despite even
partial agonistic activity in vitro, evident from an increase
in ErbB2 phosphotyrosine level and accelerated receptor
turnover by antibody-mediated receptor crosslinking.
42 In
contrast, a monovalent scFvFRP5–ETA fusion protein did not
induce ErbB2-tyrosine phosphorylation, indicating that the
activity of a monovalent scFv fusion protein might be limited
by the intrinsic turnover rate of its target receptor.
43 We have
own preliminary data conﬁrming an increase in ErbB2-
phosphorylation on treatment of Colo205 cells with a
conventional, homotrimeric scFvFRP5–TRAIL fusion protein,
whereas treatment with the monovalent scFv–scTRAIL had
no receptor-activating effect (data not shown). Accordingly,
the single-chain design concept might be of advantage
compared with a conventional fusion protein if target-antigen
multimerization has to be avoided. Moreover, Stagg
et al.
44 could show that combination of ErbB2 blockade and
TRAIL-R2 activation can elicit potent synergistic antitumor
activity. Thus, modifying the targeting module using an ErB2-
speciﬁc scFv antibody fragment also capable of inhibiting
ErbB2 signaling might result in further increased ErbB2-
speciﬁc antitumor activity of an scFv–TRAIL fusion protein.
The here described antitumoral activity of the scFv–scTRAIL
fusion protein, which resulted in clear reduction in tumor size
under treatment, appears superior to that of published
preclinical data with homotrimeric TRAIL, regarding both
the applied dose and the treatment periods.
7,8,40 However,
detailed side-by-side comparison of different TRAIL reagents
are required to conﬁrm this observation.
In conclusion, our data provide evidence that bioactive
single-chainTRAILfusionproteinscanbegenerated.Further-
more, fusion to a target-speciﬁc scFv antibody results
in target-dependent increase in TRAIL-mediated cytotoxicity
in vitro, likely due to efﬁcient TRAIL-R2 activation, and
improves antitumoral activity in vivo. Accordingly, this design
concept represents a promising strategy to enhance TRAIL’s
antitumoral action and to minimize potential unwanted
off-target actions on normal tissues.
Materials and Methods
Plasmids and cell lines. The pIRESpuro–scTRAIL expression construct for
human scTRAIL (aa 95–281) was generated by insertion of linker sequences,
encoding four repetitions of the GGGS motif, between the three TRAIL modules as
described previously for the construction of scTNF.
20
The single-chain antigen binding protein scFvFRP5 for the ErbB2-speciﬁc
pIRESpuro–scFv–scTRAIL expression construct was described previously.
21
HEK293, Jurkat, Colo205, SKW6.4 and L929 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA) or DSMZ – Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig,
Germany). The HT1080 cells were a kind gift of W Rettig (Boehringer Ingelheim
Pharma, Vienna, Austria). Cells were cultured in RPMI 1640 medium (Invitrogen,
Karlsruhe, Germany) supplemented with 5% or 10% (SKW6.4) fetal calf serum
(FCS, PAA Laboratories, Pasching, Austria).
Production and puriﬁcation of recombinant proteins. The TRAIL
fusion proteins were produced in HEK293 cells after stable transfection of the
corresponding expression plasmids using Lipofectamine 2000 (Invitrogen) and
selection of stable clones by limiting dilution. For protein production, stable clones
were expanded and grown in RPMI 1640, 5% FCS, to 90% conﬂuency and
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50mM ZnCl2, replacing media two times every 3 days. Supernatants were pooled
and recombinant proteins were puriﬁed by afﬁnity chromatography using anti-FLAG
mAb M2 agarose (Sigma-Aldrich, Steinheim, Germany). The bound proteins were
eluted with 100mg/ml FLAG peptide (Sigma-Aldrich) and dialyzed against PBS.
After concentrating puriﬁed proteins by dialysis on PEG35000, they were analyzed
andquantiﬁedbySDS-PAGE,silvergel(Sigma-Aldrich)andgelﬁltrationandstored
at 41C.
Gel ﬁltration. Protein samples were applied to a BioSuite250 HR SEC
(300 7.8) column (Waters, Millipore Corp., Milford, MA, USA) equilibrated in
PBS and eluted at a ﬂow rate of 0.5ml/min.
Flow cytometry. Cells (5 10
5) were incubated for 2h at 41C with the
indicated concentrations of the TRAIL fusion proteins. After washing the cells three
timeswithPBS,2%FCS,0.02%sodiumazide,boundfusionproteinsweredetected
by anti-human TRAIL mAb (MAB687) (1mg/ml, R&D Systems, Wiesbaden,
Germany) and ﬂuorescein isothiocyanate-labeled rabbit anti-mouse IgG Ab
(1mg/ml, Sigma-Aldrich). ErbB2 expression was detected by anti-c-neu (AB-5)
(1mg/ml, Merck KGaA, Darmstadt, Germany) and ﬂuorescein isothiocyanate-
labeled rabbit anti-mouse IgG Ab (1mg/ml, Sigma-Aldrich). Alternatively, cell-bound
scFv–scTRAIL was detected by TRAILR–Fc fusion proteins (5mg/ml TRAILR1-Fc
and 3mg/ml TRAILR2-Fc) and ﬂuorescein isothiocyanate-labeled anti-human IgG,
Fc-speciﬁc antibodies (Sigma-Aldrich). For competition studies, FRP5 hybridoma
supernatant or mouse IgG1 (Sigma-Aldrich) was added 30min before addition of
the scFv–scTRAIL.
Cell death assays. HT1080 cells (2 10
4/well), Colo205 cells (5 10
4/well),
SKW6.4 cells (2 10
4/well) or Jurkat cells (1 10
5/well) were cultured in 100ml
culture medium in 96-well plates. The next day, cells were treated in duplicates or
triplicates with the indicated concentrations of the TRAIL fusion proteins or
‘Killer-TRAIL’ (Axxora Deutschland GmbH, Lo ¨rrach, Germany). After over night
incubation, cell viability was determined either by crystal violet staining (HT1080) or
the MTT method (Jurkat, Colo205, SKW6.4),
45 except that for MTT staining a lysis
buffer consisting of 15% SDS in DMF/dH2O (1:1), pH4.5 (with 80% acetic acid)
was used. To show target antigen- and TRAIL-R2-dependent induction of cell
death, cells were preincubated for 30min with FRP5 hybridoma supernatant
46
(B10mg/ml) or a competing ErbB2 peptide (10mg/ml) encompassing the
FRP5-binding epitope
21 or a neutralizing TRAIL-R2-speciﬁc Fab preparation
(50mg/ml),respectively.ForinhibitionofTRAILbioactivity,anti-TRAILantibody2E5
(1mg/ml, Axxora Deutschland GmbH) was used. For co-culture assays, 1 10
4
Colo205 and 1 10
4 L929 cells/well were seeded in 96-well plates. The next day,
cells were challenged in duplicates with scTRAIL and scFv–scTRAIL, respectively.
Afteradditional16h,cellviabilitywasdeterminedusingtheMTTmethod.Celldeath
assayswithHT1080andColo205cellswereperformedinthepresenceof2.5mg/ml
cycloheximide (Sigma-Aldrich) to sensitize cells for the induction of cell death.
Pharmacokinetics. Animal care and all experiments performed were in
accordance with federal guidelines and have been approved by the University and
State authorities. Balb/c mice (female, 7 weeks, weight between 18 and 20g,
3 mice/group) received an i.v. injection of 400pmol of the recombinant proteins in
atotalvolumeof100ml.Intimeintervalsof2, 6,20,60,120,240,360minand24h,
blood samples (B100ml) were taken from the tail and incubated on ice. Clotted
blood was centrifuged at 10000g for 10min, 41C, and serum samples were stored
at  801C. Serum concentrations of recombinant proteins were ﬁnally determined
by ELISA (BD Biosciences, Heidelberg, Germany). For calculation, relative values
of serum concentrations were analyzed with the ﬁrst value (2min) being set to
100%.GraphPadPrismSoftwarewas usedforcurveﬁttingby nonlinearregression.
ThepharmacokineticparametersAUC,t 1
2aandt 1
2bwerecalculatedbyExcelusing
the ﬁrst 3 times points to calculate t 1
2a and the last three time points to calculate
t 1
2b. Statistics were determined by the unpaired t-test.
Xenograft mouse models
Local treatment. Six-week-old female NMRI nu/nu mice (Janvier Laboratories,
LeGenest-Saint-Isle,France)wereinjecteds.c.with3 10
6Colo205cellsin100ml
PBS.Treatmentstarted whentumorsreachedB25mm
2. Micereceived4daily s.c.
injections of 1nmol of the various TRAIL fusion proteins in concentrated cell-culture
supernatant. Supernatants were concentrated by dialysis on PEG35000.
The control group received 100ml concentrated cell-culture supernatant from
empty vector-transfected cells at the same time intervals.
Systemictreatment. Colo205cells(3 10
6)in100mlPBSweres.c.inoculated
at the left and right dorsal sides of 6-week-old female NMRI nu/nu mice. Treatment
started 5 days after tumor cell inoculation when tumors reached B25mm
2. Mice
received 8 daily i.v. injections of 1nmol of the afﬁnity puriﬁed TRAIL fusion proteins.
The control group received 100ml PBS at the same time intervals. Tumor growth
was monitored as described.
47
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